Search results

Skip to results

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Your search for Apnea returned no results
Showing 46 to 60 of 68 results for apnoea

  1. Intramuscular diaphragm stimulation for ventilator-dependent chronic respiratory failure caused by motor neurone disease (IPG593)

    Evidence-based recommendations on intramuscular diaphragm stimulation for ventilator-dependent chronic respiratory failure in people with motor neurone disease. This involves implanting electrodes into the diaphragm to make it contract. This gradually strengthens the diaphragm and may eventually help the person to breathe without a ventilator.

  2. Weight management: lifestyle services for overweight or obese children and young people (PH47)

    This guideline covers lifestyle weight management services for children and young people aged under 18 who are overweight or obese. It advises how to deliver effective weight management programmes that support children and young people to change their lifestyle and manage their weight.

  3. Community pharmacies: promoting health and wellbeing (NG102)

    This guideline covers how community pharmacies can help maintain and improve people’s physical and mental health and wellbeing, including people with a long-term condition. It aims to encourage more people to use community pharmacies by integrating them within existing health and care pathways and ensuring they offer standard services and a consistent approach. It requires a collaborative approach from individual pharmacies and their representatives, local authorities and other commissioners.

  4. InterDry for intertrigo (MIB192)

    NICE has developed a medtech innovation briefing (MIB) on InterDry for intertrigo .

  5. In moderate OSAHS, which clinical and physiological phenotypes predict treatment response to customised mandibular advancement splints?

    Source guidance details Comes from guidance Obstructive sleep apnoea/hypopnoea syndrome and obesity hypoventilation syndrome in over 16s

  6. Mandibular advancement splints for severe OSAHS: What is the clinical and cost effectiveness of mandibular advancement splints for managing severe OSAHS?

    Source guidance details Comes from guidance Obstructive sleep apnoea/hypopnoea syndrome and obesity hypoventilation syndrome in over 16s

  7. Mandibular advancement splints for mild symptomatic OSAHS and moderate OSAHS: In mild symptomatic OSAHS, which clinical and physiological phenotypes predict treatment response to customised mandibular advancement splints?

    Source guidance details Comes from guidance Obstructive sleep apnoea/hypopnoea syndrome and obesity hypoventilation syndrome in over 16s

  8. Oxygen therapy for OSAHS: What is the clinical and cost effectiveness of nocturnal oxygen compared with placebo in people with OSAHS who are unable to tolerate CPAP?

    Source guidance details Comes from guidance Obstructive sleep apnoea/hypopnoea syndrome and obesity hypoventilation syndrome in over 16s

  9. Upper airway surgery in people unable to tolerate or adhere to CPAP: What is the clinical and cost effectiveness of upper airway surgical interventions for people with OSAHS who are unable to tolerate or adhere to CPAP?

    Source guidance details Comes from guidance Obstructive sleep apnoea/hypopnoea syndrome and obesity hypoventilation syndrome in over 16s

  10. Treatment for people with COPD–OSAHS overlap syndrome: What is the optimal treatment for people with COPD–OSAHS overlap syndrome: non-invasive ventilation or CPAP?

    Source guidance details Comes from guidance Obstructive sleep apnoea/hypopnoea syndrome and obesity hypoventilation syndrome in over 16s

  11. What is the clinical and cost effectiveness of auto- and fixed-level continuous positive airway pressure (CPAP) for managing moderate and severe OSAHS?

    Source guidance details Comes from guidance Obstructive sleep apnoea/hypopnoea syndrome and obesity hypoventilation syndrome in over 16s

  12. Neonatal infection: antibiotics for prevention and treatment (NG195)

    This guideline covers preventing bacterial infection in healthy babies of up to and including 28 days corrected gestational age, treating pregnant women whose unborn baby is at risk of infection, and caring for babies of up to and including 28 days corrected gestational age with a suspected or confirmed bacterial infection. It aims to reduce delays in recognising and treating infection and prevent unnecessary use of antibiotics. The guideline does not cover viral infections.

  13. The Vest for delivering high-frequency chest wall oscillation in people with complex neurological needs (MIB159)

    NICE has developed a medtech innovation briefing (MIB) on The Vest for delivering high-frequency chest wall oscillation in people with complex neurological needs .

  14. Cerebral palsy in under 25s: assessment and management (NG62)

    This guideline covers diagnosing, assessing and managing cerebral palsy in children and young people from birth up to their 25th birthday. It aims to make sure they get the care and treatment they need for the developmental and clinical comorbidities associated with cerebral palsy, so that they can be as active and independent as possible.